- Stock Skyrockets: Quantum Computing Inc. (NASDAQ: QUBT) shares have exploded in 2025 – up over 2,500% year-on-year – including a +23% jump on October 3, 2025 alone. The stock closed that day at $24.62 (third straight day of gains) amid frenzied trading and quantum-tech hype.
- Massive Cash Infusion: QUBT raised an oversubscribed $500 million (later upsized to $750 million) via private placement at market price, adding a huge cash war chestts2.techgurufocus.com. Total capital since late 2024 is ~$1.64 billion, giving QUBT “the strongest balance sheet among publicly traded quantum companies” and funding through 2028, according to CEO Dr. Yuping Huangthequantuminsider.com.
- New Quantum Tech Debut: On Sept 29, QUBT unveiled its “Quantum Secure Solution,” a room-temperature photonic encryption network showcased at ECOC 2025ts2.tech. This platform uses time-energy entangled light (no cryogenics needed) to secure communications against future quantum decryption threats – a “significant technological milestone” built for real-world deployment today, says CEO Huangts2.techquantumcomputinginc.com.
- Analyst Upgrades & Buzz:Ascendiant Capital just hiked QUBT’s price target to $40 (from $22) and reiterated a Buy rating, implying big upsidets2.tech. A Barron’s piece trumpeted that QUBT stock “could rise 86%” furtherts2.tech. Earlier, Lake Street Capital initiated coverage at Buy ($24 target) on Sept 18mitrade.com. The quantum sector’s momentum – “big deals, social media buzz, and fresh capital” driving a “Quantum Four” rally – has swept up QUBT along with peers like Rigetti, D-Wave, and IonQswingtradebot.comts2.tech.
- Soaring Valuation vs. Tiny Revenues: Despite a market cap around $4–5 billion, QUBT’s revenues are almost nil. In Q2 2025 it reported only $61,000 in sales (down 67% YoY) against a $36.5 million net loss, and full-year revenue is under $0.3 Mts2.techgurufocus.com. That puts QUBT at a stratospheric 12,000× price-to-sales ratiogurufocus.com. “Very limited revenue” and ongoing cash burn are major concerns, analysts warnts2.tech. Even after raising hundreds of millions, QUBT remains unprofitable with essentially infinite current P/E.
- Investor Sentiment – Hype vs. Skepticism: QUBT’s story has captivated speculators – it literally has “quantum computing” in its name – fueling what some call a quantum bubble. Momentum bulls tout its breakthroughs and huge cash hoard as signs of a “quantum gold rush.” At the same time, critics highlight red flags: insider selling (executives cashed out shares during the run-up)ts2.techgurufocus.com, heavy dilution, and even a shareholder lawsuit alleging exaggerated tech claimsts2.tech. As one analysis put it, “Heavy losses, dilution, and legal uncertainties remain at the forefront” of the bear casets2.tech. The Motley Fool notes plenty of pundits questioning whether QUBT is the best way to play quantum, yet “in the near term, hope and hype could continue” propelling the stocksharewise.comsharewise.com.
- Path Forward – Spending Big to Win Big: Flush with cash, QUBT is aggressively investing in its future. The company plans to accelerate commercialization, expand manufacturing, hire talent, and pursue strategic acquisitions with its new fundsthequantuminsider.comgurufocus.com. “Our focus now shifts to expedite the transition from a quantum technology innovation company to a leading quantum hardware manufacturer,” CEO Huang said, aiming to put “quantum into the hands of people”thequantuminsider.com. QUBT has already opened a photonic chip foundry in Arizona to produce its own quantum-optics hardwarets2.tech, and it has notched early partnerships & pilot deals – from a NASA subcontract (using QUBT’s photonic computer for space data) to a NIST contract for quantum chips, and even a $332K sale to a top-5 bank for a quantum cybersecurity testbedts2.techts2.tech. These initial customers lend some credibility to QUBT’s technology in real-world use.
- Showdown in the Quantum Sector: QUBT’s wild run comes amid a broader quantum-computing boom. Fellow “Quantum Four” stocks Rigetti (RGTI), D-Wave (QBTS), and IonQ (IONQ) have all soared in 2025ts2.tech. In fact, QUBT’s +2,517% one-year gain outpaced even IonQ’s +705% jumpts2.tech, though IonQ is far larger and reported $20.7 M Q2 revenue (projected ~$90 M for 2025)ts2.tech. Rigetti and D-Wave – while unprofitable – each generate a few million in quarterly salests2.tech, unlike QUBT’s near-zero revenue. QUBT’s approach (photonic qubits at room-temp) differs from IonQ’s trapped ions or D-Wave’s annealing, but all are racing to achieve useful quantum computing. Even tech giants like IBM and Google loom large with their own quantum R&Dts2.tech. Thanks to its huge capital raise, QUBT now boasts more cash (>$1.5 B) than many competitors (e.g. Rigetti had ~$570 M mid-2025)ts2.tech. This financial firepower could allow QUBT to buy or build its way to technological leadership – if it can execute.
- Outlook: High Risk, High Reward: The coming months will test whether QUBT can turn its big promises into real progress. Bulls believe the company’s photonic tech (like the new Quantum Secure network) could leapfrog rivals and tap urgent needs in cybersecurity and AI. With retail traders and some analysts on board, any further breakthroughs or big-name partnerships could extend the rally. However, skeptics counter that fundamentals must catch up. At some point, quantum-hype alone won’t justify a multi-billion valuation if revenues stay microscopic. Analysts currently have mixed views (average rating between Buy and Hold, with price targets ranging from ~$15 to $40)ts2.techmitrade.com. Volatility remains extreme (QUBT’s beta ~5), so investors should brace for turbulencegurufocus.comgurufocus.com. In essence, QUBT embodies both the enormous potential and stark uncertainty of the quantum computing revolution. As one financial commentator observed, only time will tell if QUBT “lives up to expectations” or not – but for now, the company has ignited a speculative fervor that has few parallels in 2025sharewise.comts2.tech.
Quantum Computing Inc’s Quantum Gold Rush: $750 M Windfall, New Tech & a Stock Surge for the Ages
Latest articles
ImmunityBio Faces FDA Decision on Bladder-Cancer Application, Risk Remains
The FDA accepted ImmunityBio’s application to expand Anktiva’s use with BCG in papillary-only, BCG-unresponsive non-muscle invasive bladder cancer, setting a Jan. 6, 2027 decision date. ImmunityBio reported $44.2 million in first-quarter net product revenue and held $380.9 million in cash and equivalents. Shares last traded at $7.76, down 2.8%. The filing is supported by data from 80 patients in a Phase 2/3 trial.
AmpliTech Jumps After 5G Approval Clears North America Sales Path
AmpliTech received U.S. and Canadian certification for its full indoor 5G Native DAS hardware, enabling immediate commercial sales and integration across North America. Shares rose about 14% in premarket trading after the announcement. The company said it has orders from a North American mobile network operator, with shipments set to begin later this year.
Intuit’s Q3 Numbers Land as Shares Down 39%
Intuit will report fiscal third-quarter results after U.S. markets close Wednesday, following a 39% stock drop over the past year. Analysts expect earnings of $12.57 per share on $8.54 billion revenue, both up from last year. The quarter covers peak tax season for TurboTax and QuickBooks. Intuit shares closed at $399.71 Tuesday, down 0.9%.
